Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Langer

Showing results (91-100 of 199) with videos related to

Pageof 20
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted TherapyEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2003
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposidePatricia E Schroeder, Peter Buhl Jensen, Maxwell Sehested, et al.
Lung Cancer (Amsterdam, Netherlands)|November 27, 2007
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trialMorten Sorensen, Ulrik Lassen, Torben Palshof, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2003
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agentPatricia E Schroeder, Kenneth Francis Hofland, Peter Buhl Jensen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 10, 2006
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapyJ Herrstedt, T C Sigsgaard, H A Nielsen, et al.
Toxicology|January 19, 2010
A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damageAnnemette V Thougaard, Seppo W Langer, Bo Hainau, et al.
Psychophysiology|January 1, 1985
Cardiopulmonary adjustments during exercise and an aversive reaction time task: effects of beta-adrenoceptor blockadeA W Langer, J A McCubbin, C M Stoney, et al.
Psychophysiology|January 1, 1985
On-line minicomputerized measurement of cardiopulmonary function on a breath-by-breath basisA W Langer, J S Hutcheson, J D Charlton, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2019
Erratum to "Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence" [Lung Cancer 132 (June) (2019) 141-149]V Grøndahl, T Binderup, S W Langer, et al.
Thescientificworldjournal|September 14, 2012
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomasIngrid H Olsen, Jens B Sørensen, Birgitte Federspiel, et al.
Pageof 20

Showing results (91-100 of 199) with videos related to

Sort By:
Pageof 20
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2022
Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted TherapyEsben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2003
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposidePatricia E Schroeder, Peter Buhl Jensen, Maxwell Sehested, et al.
Lung Cancer (Amsterdam, Netherlands)|November 27, 2007
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trialMorten Sorensen, Ulrik Lassen, Torben Palshof, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2003
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agentPatricia E Schroeder, Kenneth Francis Hofland, Peter Buhl Jensen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 10, 2006
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapyJ Herrstedt, T C Sigsgaard, H A Nielsen, et al.
Toxicology|January 19, 2010
A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damageAnnemette V Thougaard, Seppo W Langer, Bo Hainau, et al.
Psychophysiology|January 1, 1985
Cardiopulmonary adjustments during exercise and an aversive reaction time task: effects of beta-adrenoceptor blockadeA W Langer, J A McCubbin, C M Stoney, et al.
Psychophysiology|January 1, 1985
On-line minicomputerized measurement of cardiopulmonary function on a breath-by-breath basisA W Langer, J S Hutcheson, J D Charlton, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2019
Erratum to "Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence" [Lung Cancer 132 (June) (2019) 141-149]V Grøndahl, T Binderup, S W Langer, et al.
Thescientificworldjournal|September 14, 2012
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomasIngrid H Olsen, Jens B Sørensen, Birgitte Federspiel, et al.
Pageof 20